Cargando…
Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers
SIMPLE SUMMARY: There have been few reports with regard to the relevance between the SARC-F score and the prognosis in patients with gastrointestinal advanced cancers, and we aimed to elucidate these issues (n = 421, median age = 73 years). During the follow-up period, 145 patients (34.4%) died. The...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749778/ https://www.ncbi.nlm.nih.gov/pubmed/35008175 http://dx.doi.org/10.3390/cancers14010010 |
_version_ | 1784631311417212928 |
---|---|
author | Matsui, Masahiro Nishikawa, Hiroki Goto, Masahiro Asai, Akira Ushiro, Kosuke Ogura, Takeshi Takeuchi, Toshihisa Nakamura, Shiro Kakimoto, Kazuki Miyazaki, Takako Fukunishi, Shinya Ohama, Hideko Yokohama, Keisuke Yasuoka, Hidetaka Higuchi, Kazuhide |
author_facet | Matsui, Masahiro Nishikawa, Hiroki Goto, Masahiro Asai, Akira Ushiro, Kosuke Ogura, Takeshi Takeuchi, Toshihisa Nakamura, Shiro Kakimoto, Kazuki Miyazaki, Takako Fukunishi, Shinya Ohama, Hideko Yokohama, Keisuke Yasuoka, Hidetaka Higuchi, Kazuhide |
author_sort | Matsui, Masahiro |
collection | PubMed |
description | SIMPLE SUMMARY: There have been few reports with regard to the relevance between the SARC-F score and the prognosis in patients with gastrointestinal advanced cancers, and we aimed to elucidate these issues (n = 421, median age = 73 years). During the follow-up period, 145 patients (34.4%) died. The 1-year cumulative overall survival rate in patients with SARC-F ≥ 4 (recommended cutoff point, n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the overall survival, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score 1 (p = 0.0147) and 2 (p < 0.0001), ECOG-PS 2 (p < 0.0001), and 3 (p < 0.0001) and 4 (p < 0.0001) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and the best cutoff point of the SARC-F score was two. The SARC-F score appears to be useful in patients with gastrointestinal advanced malignancies. ABSTRACT: We sought to elucidate the prognostic impact of the SARC-F score among patients with gastrointestinal advanced malignancies (n = 421). A SARC-F score ≥ 4 was judged to have a strong suspicion for sarcopenia. In patients with ECOG-PS 4 (n = 43), 3 (n = 61), and 0–2 (n = 317), 42 (97.7%), 53 (86.9%) and 8 (2.5%) had the SARC-F score ≥ 4. During the follow-up period, 145 patients (34.4%) died. All deaths were cancer-related. The 1-year cumulative overall survival (OS) rate in patients with SARC-F ≥ 4 (n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the OS, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score (GPS) 1 (p = 0.0147, GPS 0 as a standard), GPS 2 (p < 0.0001, GPS 0 as a standard), ECOG-PS 2 (p < 0.0001, ECOG-PS 0 as a standard), ECOG-PS 3 (p < 0.0001, ECOG-PS 0 as a standard), and ECOG-PS 4 (p < 0.0001, ECOG-PS 0 as a standard) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and best cutoff point of the SARC-F score was two. In conclusion, the SARC-F score is useful in patients with gastrointestinal advanced malignancies. |
format | Online Article Text |
id | pubmed-8749778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87497782022-01-12 Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers Matsui, Masahiro Nishikawa, Hiroki Goto, Masahiro Asai, Akira Ushiro, Kosuke Ogura, Takeshi Takeuchi, Toshihisa Nakamura, Shiro Kakimoto, Kazuki Miyazaki, Takako Fukunishi, Shinya Ohama, Hideko Yokohama, Keisuke Yasuoka, Hidetaka Higuchi, Kazuhide Cancers (Basel) Article SIMPLE SUMMARY: There have been few reports with regard to the relevance between the SARC-F score and the prognosis in patients with gastrointestinal advanced cancers, and we aimed to elucidate these issues (n = 421, median age = 73 years). During the follow-up period, 145 patients (34.4%) died. The 1-year cumulative overall survival rate in patients with SARC-F ≥ 4 (recommended cutoff point, n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the overall survival, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score 1 (p = 0.0147) and 2 (p < 0.0001), ECOG-PS 2 (p < 0.0001), and 3 (p < 0.0001) and 4 (p < 0.0001) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and the best cutoff point of the SARC-F score was two. The SARC-F score appears to be useful in patients with gastrointestinal advanced malignancies. ABSTRACT: We sought to elucidate the prognostic impact of the SARC-F score among patients with gastrointestinal advanced malignancies (n = 421). A SARC-F score ≥ 4 was judged to have a strong suspicion for sarcopenia. In patients with ECOG-PS 4 (n = 43), 3 (n = 61), and 0–2 (n = 317), 42 (97.7%), 53 (86.9%) and 8 (2.5%) had the SARC-F score ≥ 4. During the follow-up period, 145 patients (34.4%) died. All deaths were cancer-related. The 1-year cumulative overall survival (OS) rate in patients with SARC-F ≥ 4 (n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the OS, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score (GPS) 1 (p = 0.0147, GPS 0 as a standard), GPS 2 (p < 0.0001, GPS 0 as a standard), ECOG-PS 2 (p < 0.0001, ECOG-PS 0 as a standard), ECOG-PS 3 (p < 0.0001, ECOG-PS 0 as a standard), and ECOG-PS 4 (p < 0.0001, ECOG-PS 0 as a standard) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and best cutoff point of the SARC-F score was two. In conclusion, the SARC-F score is useful in patients with gastrointestinal advanced malignancies. MDPI 2021-12-21 /pmc/articles/PMC8749778/ /pubmed/35008175 http://dx.doi.org/10.3390/cancers14010010 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Matsui, Masahiro Nishikawa, Hiroki Goto, Masahiro Asai, Akira Ushiro, Kosuke Ogura, Takeshi Takeuchi, Toshihisa Nakamura, Shiro Kakimoto, Kazuki Miyazaki, Takako Fukunishi, Shinya Ohama, Hideko Yokohama, Keisuke Yasuoka, Hidetaka Higuchi, Kazuhide Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers |
title | Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers |
title_full | Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers |
title_fullStr | Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers |
title_full_unstemmed | Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers |
title_short | Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers |
title_sort | prognostic impact of the sarc-f score in gastrointestinal advanced cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749778/ https://www.ncbi.nlm.nih.gov/pubmed/35008175 http://dx.doi.org/10.3390/cancers14010010 |
work_keys_str_mv | AT matsuimasahiro prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT nishikawahiroki prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT gotomasahiro prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT asaiakira prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT ushirokosuke prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT oguratakeshi prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT takeuchitoshihisa prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT nakamurashiro prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT kakimotokazuki prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT miyazakitakako prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT fukunishishinya prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT ohamahideko prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT yokohamakeisuke prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT yasuokahidetaka prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers AT higuchikazuhide prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers |